



Financial Tear Sheet

Corporate Profile

Rigel's current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent ITP. The investigation of fostamatinib also includes Phase 2 clinical trials for autoimmune hemolytic anemia (AIHA) and IgA nephropathy (IgAN). In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.

Recent News

Date	Title
10/10/17	Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
10/04/17	Rigel Announces Pricing Of Public Offering Of Common Stock

Stock Performance

RIGL (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$4.23
Change (%)	+ 0.36 (9.30%)
Volume	3,596,250
Data as of 10/17/17 4:00 p.m. ET Refresh quote	



Data provided by Nasdaq. Minimum 15 minutes delayed.

SEC Filings

Filing Date	Form
10/05/17	424B5
10/05/17	8-K

Primary IR Contact

Ryan Maynard
 CFO
 Phone: (650) 624-1284
 E-mail: invrel@rigel.com